Arrowhead Pharmaceuticals’ Price Target Cut to $78 from $81 by Morgan Stanley
Morgan Stanley lowered Arrowhead Pharmaceuticals’ price target to $78 from $81, reflecting revised valuation assumptions. The adjustment signals tempered expectations for the company's upcoming catalysts and may pressure near-term share performance.
1. Morgan Stanley Lowers Price Target
On February 7, Morgan Stanley reduced its 12-month price target on Arrowhead Pharmaceuticals to $78 from $81. The firm cited revised valuation assumptions for the biotech’s lead programs and adjusted revenue forecasts. This cut may influence investor sentiment and elevate trading volatility in the near term.
Related News
GS
Goldman Sachs’ Marcus Launches 9-Month CD at 4% APY to Boost Deposits
GS•
DE
Menon Bearings Posts 23% Revenue Gain, 51 New Parts for Deere Supply
DE•
AMZN
AWS Faces Challenge as Nvidia Forecasts $91B Q3 Sales, Musk Eyes 2028 Space Data Centers
AMZN•
RLAY
Relay Therapeutics Prices 22.9M Shares at $12 to Raise $275M
RLAY•
WMT
Walmart Set for Q1 EPS of $0.66 on $175B Revenue; Value Outlook Tempered
WMT•
Sources
F